|
Females, %
|
72.7%
|
66.9%
|
|
Ethnicity:
|
|
Caucasian
|
74.6%
|
73.4%
|
|
Black
|
2.1%
|
0.0%
|
|
Hispanic
|
6.7%
|
4.5%
|
|
Asian
|
8.9%
|
16.2%
|
|
other
|
7.6%
|
5.8%
|
|
Age at study baseline, mean years (SD)
|
45.1 (2.8)
|
56.2 (4.2)
|
|
Age at onset of clinical symptoms, mean years (SD)
|
41.6 (5.9)
|
50.7 (7.5)
|
|
RRMS, %a
|
96.3%
|
94.9%
|
|
SPMS, %b
|
3.7%
|
5.1%
|
|
MS duration since onset of symptoms, mean years (SD)
|
3.9 (5.2)
|
5.9 (7.1)
|
|
Relapses during last 2 years,a mean number (SD)
|
1.7 (1.0)
|
1.6 (1.1)
|
|
≥2 relapses during last 2 years,a %
|
55.6%
|
52.7%
|
|
EDSS, mean (SD)
|
2.5 (1.5)
|
3.1 (1.9)
|
|
EDSS ≥3, %
|
41.6%
|
52.0%
|
|
Cranial MRI performed, %
|
96.3%
|
94.0%
|
|
Contrast-enhancing lesions, %
|
28.8%
|
22.7%
|
|
DMT use prior to BEACON, %
|
14.1%
|
13.6%
|
